A randomized trial at MD Anderson Cancer Center found that personalized navigation support raised BRCA genetic testing uptake ...

Myriad Genetics, SOPHiA GENETICS and AstraZeneca are collaborating to advance Myriad’s prostate cancer genomic instability ...

AI-based research identifies ZNF268 as a potential marker of prostate cancer progression, raising hopes for more accurate ...

LOS ANGELES--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new ...

LOS ANGELES, November 20, 2025--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) is proud to announce the launch of an interactive website and downloadable guide, Somatic and Germline Genetic ...

Findings from a study exploring how AI-driven NCCN guideline interpretation can optimize genetic testing and reduce clinician burden in prostate cancer. Keeping pace with rapid updates to NCCN ...

LOS ANGELES, February 24, 2026--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of ...

"Is cancer genetic testing something that is passed down to family members?" Have you ever felt anxious about that?By reading ...

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate ...

Background: There is limited research examining demographic, disease-related, and social factors that may influence veterans’ participation in germline genetic testing. This study sought to identify ...